GLO1 and ovarian carcinoma: From the exploration of novel biomarkers like RAGE to the potential therapeutic implications of Glo1, ongoing research offers hope for improved diagnostic methods and targeted treatments, aiming for better outcomes in the battle against ovarian cancer.